Checking your facts via Google "......BMY would acquire MEDX and its antibody-based therapeutics platform for $2.4 billion. No matter how you slice it, this deal is a rich one, offering MEDX shareholders a 90% premium to the stock’s prior-day price and a price to revenue multiple of 47.1x.....The company’s current product pipeline includes ipilimumab, a Phase III clinical trial product in development with BMY for the treatment of metastatic melanoma and other cancers. MEDX also has numerous Phase II clinical trial products; one of MEDX’s partners is AstraZeneca (NYSE: AZN), which acquired the partnership when it bought MedImmune in 2007 for $15.2 billion. ...."
Thus, assuming CLDX & MEDX equal pipelines, etc. then $2.4 B would be 3.6x higher than CLDX current market cap of $671 MM (or $7 share x 3.6 = $25 share price).
.... Given CLDX's phase III trial products, I expect a much CLDX share price later this year. However, if you are current about a near term buyout then after having added even more shares today will have a very nice profit.
Good luck CLDX longs (and especially former MEDX longs). Cheers
BMY's Opdivo is the same immunotherapy science techonology as CLDX (as BMY purchased from MEDX) ... see article below. This is why I am still holding and recently purchased more CLDX.
Good luck longs.
Bristol-Myers shares could rise 25 pct on cancer drug-Barron's
7 hours ago
NEW YORK, Feb 14 (Reuters) - Shares of Bristol-Myers Squibb could rise 25 percent within a year because of its cancer-fighting drug Opdivo, which some analysts see generating $8 billion to $9 billion in annual sales in five years, Barron's said in its latest edition.
The drug's success in thwarting a number of cancers, including lung, melanoma, renal cell carcinoma, and head and neck, provides a major opportunity for Bristol-Myers, the publication said.
Bristol-Myers holds an 80 percent share of the fledgling immuno-oncology market, and even as competition increases with treatments, the company is expected to retain a 50 percent to 60 percent share, Barron's said.
Bristol-Myers in late January forecast 2016 earnings that would represent a gain of almost 20 percent over last year, which would make the company the pharmaceutical industry's earnings-growth pacesetter, Reuters reported at the time.